AstraZeneca Pharma India Ltd. - Research Center
506820 ASTRAZEN Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | Sep ' 19 | |
|---|---|---|---|---|---|
| Sales | 432.49 | 373.11 | 403.05 | 418.76 | 413.04 |
| Operating profit | 52.63 | 33.55 | 64.33 | 51.55 | 69.12 |
| Interest | 0.44 | 0.51 | 0.55 | 0.54 | 0.58 |
| Gross profit | 61.21 | 38.78 | 71.14 | 57.85 | 74.69 |
| EPS (Rs) | 15.76 | 8.88 | 17.99 | 14.51 | 14.37 |
Half yearly
results in details
| Mar ' 22 | Sep ' 21 | Sep ' 20 | Mar ' 20 | Sep ' 19 | |
|---|---|---|---|---|---|
| Other income | 9.01 | 5.74 | 7.36 | 6.84 | 6.15 |
| Stock adjustment | 15.53 | -1.06 | -11.12 | -41.11 | 1.90 |
| Raw material | 49.30 | 40.31 | 44.83 | 38.17 | 32.04 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 117.73 | 112.48 | 111.99 | 133.80 | 102.90 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | -20.12 | 20.12 | 20.73 | 24.76 | 31.00 |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 217.43 | 167.71 | 172.30 | 211.58 | 176.09 |
| Provisions made | - | - | - | - | - |
| Depreciation | 7.91 | 9.04 | 9.18 | 9.32 | 9.27 |
| Taxation | 13.89 | 7.55 | 16.98 | 12.25 | 29.49 |
| Net profit / loss | 39.40 | 22.19 | 44.97 | 36.28 | 35.93 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 12.17 | 8.99 | 15.96 | 12.31 | 16.73 |
| GPM (%) | 13.86 | 10.24 | 17.33 | 13.59 | 17.82 |
| NPM (%) | 8.92 | 5.86 | 10.96 | 8.52 | 8.57 |
Mutual Fund Selector
Find the fund that is right for you
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis